| CDK7 inhibition suppresses castration-resistant prostate cancer through MED1 inactivation R Rasool, R Natesan, Q Deng, S Aras, P Lal, S Sander Effron, ... Cancer discovery 9 (11), 1538-1555, 2019 | 94 | 2019 |
| A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy M Makvandi, K Xu, BP Lieberman, RC Anderson, SS Effron, HD Winters, ... Cancer research 76 (15), 4516-4524, 2016 | 92 | 2016 |
| Epigenetic regulation of chromatin in prostate cancer R Natesan, S Aras, SS Effron, IA Asangani Prostate Cancer: Cellular and Genetic Mechanisms of Disease Development and …, 2019 | 11 | 2019 |
| CDK7 inhibition suppresses castration-resistant prostate cancer through MED1 inactivation. Cancer Discov. 2019; 9: 1538–1555. doi: 10.1158/2159-8290 RU Rasool, R Natesan, Q Deng, S Aras, P Lal, SS Effron, ... CD-19-0189.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 8 | |
| Targeting transcriptional addiction in anti-androgen refractory castration-resistant prostate cancer R Rasool, R Natesan, Q Deng, S Aras, SS Effron, SS Effron, ... Cancer Research 80 (16_Supplement), 1262-1262, 2020 | | 2020 |
